USD1 Trading Competition Reaches Midway Point: Veteran Meme "EGL1" Surges to the Top, New Coins "BIG DON" and "An" Temporarily Follow Behind
BlockBeats News, January 20, according to GMGN monitoring, the BNB Chain 10-day "USD1 Trading Competition" has now reached its fifth day. As the community generally believes that the winning projects are likely to get listed on top exchanges, this event has quickly spawned several new Meme coins using USD1 as a liquidity pool (such as "安", "BIG DON"), whose market caps have soared, while also injecting a new round of market expectations into some older projects (such as EGL1, CDL). The recently popular Meme coin "1" may have also seen its market cap rise due to having a USD1 liquidity pool.
The current top three tokens by market cap are as follows:
EGL1: Market cap is temporarily reported at $29.7 million, currently priced at approximately $0.0297;
BIG DON: Market cap is temporarily reported at $29.5 million, currently priced at approximately $0.0295;
安: Market cap is temporarily reported at $2,700, currently priced at approximately $0.027.
It is reported that the top three in this trading competition will receive multiple incentive supports. There are no restrictions on the token creation time for participation. Eligible USD1 trading pairs mainly include: projects created on Four meme using USD1 as the base token, or other Four meme projects with active USD1 liquidity pools.
There are currently many Meme coins with the same name in the market. The tokens with the highest liquidity at present are:
EGL1: 0xf4b385849f2e817e92bffbfb9aeb48f950ff4444
BIG DON: 0x71429f2e1e243b451b939a2af2b69fa646064444
“安”: 0x126976da699d5ad0815eb134286fc6ca53e04444
BlockBeats reminds users that Meme coin trading is highly volatile, mostly relying on market sentiment and hype, and has no actual value or use case. Investors should be aware of the risks.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - RBC expects gradual improvement in North American and European building materials stocks in the third quarter
October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
